Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.
about
Other targeted drugs in melanomaFirst-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.Targeting protein kinase-b3 (akt3) signaling in melanoma.Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors.Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.Overcoming resistance to BRAF inhibitors.Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Deconstructing Signaling Pathways in Cancer for Optimizing Cancer Combination Therapies.MEK inhibitors for the treatment of NRAS mutant melanomaDual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapyMelanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
P2860
Q26775594-3B56D5CF-6568-48F9-9DA3-DDA478FDF894Q37281257-C2E75687-2664-42B4-AC19-D9EFC72F8DC3Q38752466-4953E145-FCB1-4C07-957C-F603E930D200Q38764663-F498764F-BBA4-44DB-BA98-278D4D4E168AQ38825141-E81DE0BE-E6DC-4BDA-82A7-68CB0929B8C3Q38998443-7216044D-6B18-4AAF-8398-A3618CFCBD91Q39074281-58167ABE-67FF-4E8B-85D7-067E3657D91BQ39329582-CCA04190-9192-4BAD-8BA8-5F07253746FBQ39474116-FEE45AE3-4243-436E-B7D8-BF25FC62999FQ41471269-6BBC79A4-F6FC-4F56-8EEE-CC3266A05047Q43298157-110B4D7A-9B9C-42CA-AC9D-92550FD340DCQ47566725-36C19029-19E6-497C-8A26-769662D9A2BDQ47924964-EB52B037-8B38-4099-A3E3-3A4ED656B053Q50285246-DFE7CD89-648E-4041-B42C-7AB6784FD5A9Q53705974-944D9CD1-2DD4-4A51-8F6D-1F58A2E02B08Q54969934-481093D7-DBB7-4F00-9B99-D4B984E8BBB6Q56889985-1FF99BEA-625C-48B1-BDB4-B6A2B87DCF5EQ57072192-EB92A2D1-74CD-4F5F-835C-0E9D9CCBA852Q58751951-F4881B4C-CBD0-4C76-92B1-5C934D5433EC
P2860
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Inhibitors of pan-PI3K Signali ...... F-Mutant Melanoma Cell Growth.
@ast
Inhibitors of pan-PI3K Signali ...... F-Mutant Melanoma Cell Growth.
@en
type
label
Inhibitors of pan-PI3K Signali ...... F-Mutant Melanoma Cell Growth.
@ast
Inhibitors of pan-PI3K Signali ...... F-Mutant Melanoma Cell Growth.
@en
prefLabel
Inhibitors of pan-PI3K Signali ...... F-Mutant Melanoma Cell Growth.
@ast
Inhibitors of pan-PI3K Signali ...... F-Mutant Melanoma Cell Growth.
@en
P2093
P2860
P356
P1476
Inhibitors of pan-PI3K Signali ...... F-Mutant Melanoma Cell Growth.
@en
P2093
Bruce C Baguley
Emma Wrightson
Gordon W Rewcastle
Melanie Sweetlove
Peter R Shepherd
Sharada Kolekar
Stephen M F Jamieson
P2860
P356
10.3389/FONC.2015.00135
P577
2015-06-16T00:00:00Z